FDA Section 361 vs 351 HCT/P Compliance Checklist

A rigorous FDA Section 361 versus 351 HCT/P compliance checklist for practices requires clinical teams to verify minimal manipulation, strictly homologous intended use, the absence of systemic metabolic action, and complete donor-eligibility documentation before procuring any allograft. Because administering non-compliant Section 351 biologics exposes medical facilities to regulatory injunctions, payer clawbacks, and severe liability, practice administrators cannot rely on vendor representations alone. This operational framework outlines the specific verification steps medical directors and procurement managers must execute to ensure total compliance.

Understanding the Regulatory Framework: 21 CFR Part 1271

For medical practice managers overseeing procurement and risk management in regenerative medicine, understanding the Public Health Service (PHS) Act is foundational. The FDA regulates HCT/Ps under a tiered, risk-based framework outlined in 21 CFR Part 1271. The distinction between Section 361 and Section 351 dictates whether a product can be legally purchased and utilized in an outpatient setting without an active clinical trial protocol.

What Qualifies as a Section 361 HCT/P?

To be regulated solely under Section 361 of the PHS Act, an HCT/P must meet all four of the following criteria set forth in 21 CFR 1271.10(a):

1. Minimal Manipulation: For structural tissue (such as amniotic membrane or Wharton's Jelly connective tissue matrix), processing must not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. For cells or nonstructural tissues, processing must not alter the relevant biological characteristics.
2. Homologous Use Only: The product must perform the same basic function or functions in the recipient as in the donor, as reflected by the labeling, advertising, and objective intent of the manufacturer.
3. No Combination with Another Article: The HCT/P cannot be combined with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided the addition does not raise new clinical safety concerns.
4. No Systemic Effect (with limited exceptions): Either the HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function, OR, if it does have a systemic effect or is dependent on living cells, it must be for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.

When Does a Product Cross into Section 351?

If an allograft or cellular product fails to meet even one of the four criteria above, it defaults to regulation under Section 351 of the PHS Act as a drug, device, or biological product. Section 351 products require an approved BLA to be marketed commercially, or an active IND application to be administered to patients.

In the outpatient regenerative medicine market, regulatory exposure typically arises when a tissue bank or distributor markets an allogeneic product (such as umbilical cord blood, Wharton's Jelly, or exosomes) as a Section 361 tissue, despite processing methods that constitute "more than minimal manipulation" (e.g., enzymatic digestion, micronization that alters structural integrity, or culture expansion) or marketing claims that imply non-homologous, systemic, or metabolic functions.

FDA Section 361 versus 351 HCT/P Compliance Checklist for Practices

Practice administrators should integrate the following checklist into their standard vendor onboarding and annual compliance audits when evaluating biologics.

1. Vendor Registration and Establishment Status

• Verify FDA FEI Number: Confirm the tissue bank's FDA Establishment Identifier (FEI) using the FDA's public Human Cell and Tissue Establishment Registration (HCTERS) database. Note that registration is a self-reporting requirement and does not equal FDA approval.
• Check for AATB Accreditation: Determine if the source tissue bank holds accreditation from the American Association of Tissue Banks (AATB), which indicates adherence to rigorous industry standards for donor screening and tissue recovery.
• Verify State Licensure: Ensure both the manufacturing laboratory and the supplying distributor hold all required state-level tissue bank or medical device distribution licenses (such as Texas Department of State Health Services licensure).
• Audit Enforcement History: Search the FDA Warning Letters and Untitled Letters databases for the manufacturer, parent company, and distributor names to identify any history of regulatory citations regarding unapproved 351 products.

2. Product Documentation and Processing Review

• Request the TRG Letter (If Applicable): Ask whether the manufacturer has obtained a formal determination or recommendation from the FDA Tissue Reference Group (TRG) regarding the product's 361 status. Read the actual letter; ensure the product described matches the exact product you are buying.
• Scrutinize the Processing Methodology: Request standard operating procedure summaries for how the tissue is processed. If a structural tissue (like Wharton's Jelly or amniotic membrane) is decellularized, enzymatically digested, or processed into a flowable liquid in a way that destroys its physical structural matrix, evaluate whether the FDA considers this "more than minimal manipulation."
• Review the Package Insert: Ensure the package insert strictly describes homologous, structural functions (e.g., serving as a protective covering or structural cushion) rather than cellular therapy, systemic regeneration, or disease modification.

3. Donor Eligibility and Traceability

• Certificate of Analysis (CoA): Require a lot-specific CoA and donor eligibility summary with every shipment, confirming negative infectious disease testing (HIV, HBV, HCV, syphilis, WNV, Zika, etc.) and sterility testing (USP <71> or equivalent).
• Adverse Event and Recall Protocols: Establish a clear standard operating procedure (SOP) for logging lot numbers into the patient's electronic health record (EHR) to maintain a complete chain of custody from the tissue bank to the patient.

4. Internal Practice Marketing and Consent

• Audit External Marketing: Review the practice's website, social media, and patient brochures. Even if a vendor supplies a compliant 361 structural allograft, a practice can create regulatory exposure by marketing the product for non-homologous uses or making unsubstantiated disease claims (e.g., claiming to cure osteoarthritis, reverse neuropathy, or treat systemic autoimmune conditions).
• Standardize Informed Consent: Ensure patient consent forms accurately describe the allograft or autologous preparation, clearly state its regulatory status, and avoid promising guaranteed clinical outcomes.

Clinical Perspective: Implications for Treating Physicians

While practice managers focus on procurement, contracts, and documentation, treating physicians must understand how the 361 versus 351 distinction impacts clinical decision-making and medical liability. Clinicians across orthopedics, pain management, and aesthetics bear the ultimate responsibility for what is administered to a patient.

From a clinical standpoint, the regulatory boundary often hinges on the mechanism of action. If an allogeneic product is selected because the physician relies on the metabolic activity of living stem cells or paracrine signaling to achieve a systemic or non-homologous therapeutic effect, the FDA generally views that product as a Section 351 drug. Conversely, autologous preparations—such as platelet-rich plasma (PRP) prepared at the point of care using compliant centrifugation devices within the same surgical procedure—typically benefit from regulatory exemptions (21 CFR 1271.15(b)) or qualify under Section 361 when used homologously.

Physicians should collaborate closely with their practice administrators to ensure that the clinical rationale documented in the patient chart aligns with the regulatory classification of the product used. Furthermore, many practices mitigate biologic regulatory risk by pairing compliant autologous protocols with energy-based modalities—such as extracorporeal shockwave therapy (ECSWT) or high-power laser therapy—which operate under established FDA 510(k) medical device clearances.

Red Flags in Vendor Marketing

During the vendor vetting process, practice managers should treat the following sales representations as immediate compliance red flags:

• "FDA Approved" 361 Allografts: Section 361 products are never "FDA approved." They are regulated under 21 CFR Part 1271, and the facility is merely "FDA registered." A sales representative claiming FDA approval for a 361 amniotic or umbilical product is misrepresenting the law.
• Guaranteed Live Mesenchymal Stem Cell (MSC) Counts: Under Section 361, an allogeneic product cannot depend on the metabolic activity of living cells for its primary function unless used in a first- or second-degree blood relative. Vendors marketing high live-cell viability in allogeneic vials as the primary mechanism of action are directly contradicting 361 criteria.
• Mischaracterizing FDA Registration Certificates: Displaying an FDA establishment registration certificate as proof that the FDA has vetted and cleared the specific product's safety, efficacy, or 361 classification.

What This Means for Your Practice

Navigating the regenerative medicine supply chain requires structured due diligence. Practice managers should take the following concrete actions to protect their operations:

1. Conduct an Immediate Inventory Audit: List every biologic product currently in your clinic's refrigerators or freezers. Match each product to its vendor FEI number, package insert, and lot tracking log.
2. Standardize Your Vendor Vetting Packet: Do not onboard a new biologic distributor without receiving their state license, the manufacturer's AATB accreditation status, sample CoAs, and written documentation supporting their 361 classification.
3. Scrub Practice Marketing Assets: Remove any consumer-facing language that implies allogeneic tissues act as unapproved live-cell drug therapies or cure specific diseases.
4. Partner with Established Distributors: Work with licensed medical distributors who prioritize regulatory transparency and offer a diversified portfolio of compliant biologics and cleared medical devices.

If your practice is evaluating its current regenerative medicine supply chain or looking to introduce compliant biologic and device protocols, contact the team at Dallas Regenerative Solutions to schedule an operational consultation.